


# AMD: Challenges in treatment of patients

## Most significant areas of unmet needs



## Key Takeaways

- Regular (monthly) long-term follow-up's takes long duration (3 hours) and is taxing to patients and their families
- There is no effective treatment for Dry AMD and reimbursement for anti-VEGF therapies in Wet AMD is still a challenge (cheapest drug Avastin is not FDA approved)
- Patients can be in denial until later in the disease stage
- Once diagnosed, compliance is not an issue as patients are motivated to try new effective treatment
- Multiple avenues available for patient education once they are diagnosed